Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163321 | 0.98 | TSHR (0.51) | TSHRMAPK1 | |
| SCHEMBL16163238 | 0.96 | TSHR (0.53) | TSHRMAPK1 | |
| SCHEMBL16163176 | 0.88 | — | — | |
| SCHEMBL16163160 | 0.86 | — | — | |
| SCHEMBL7740569 | 0.84 | TSHR (0.53) | TSHRMAPK1 | |
| SCHEMBL16163287 | 0.83 | — | — | |
| SCHEMBL16163285 | 0.83 | TSHR (0.49) | TSHRMAPK1 | |
| SCHEMBL16163364 | 0.80 | TSHR (0.51) | TSHRMAPK1 | |
| SCHEMBL14941421 | 0.80 | TSHR (0.51) | TSHRMAPK1 | |
| SCHEMBL7745813 | 0.80 | ALDH1A1 (0.54) | TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809575-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2017-11-07 | — | — | US | claimed |
| EP-2776416-B1 | PHARMACEUTICAL COMPOUNDS | RE VIRAL LTD (GB) | 2016-01-13 | — | — | EP | claimed |
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | re: Viral Ltd (GB) | 2014-10-16 | — | — | US | claimed |
| US-9809575-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-2776416-B1 | PHARMACEUTICAL COMPOUNDS | RE VIRAL LTD (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | re: Viral Ltd (GB) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | CYP2S1, H1-2, CBR1 | TSHR 2037/4885MAPK1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.